FDA clears targeted cholangiocarcinoma therapy
MDSpire News
September 24, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

To report the FDA approval of lirafugratinib for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma.
Lirafugratinib received breakthrough therapy and orphan drug designations, with safety warnings for ocular toxicity, hyperphosphatemia, and embryo-fetal toxicity.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: